The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracycline-mediated cardiotoxicity

Hellenic Journal of Cardiology

Volumn 55, Issue 3, 2014, Pages 235-244

  Mornoş, Cristian ^a   Manolis, Athanasios J ^b   Cozma, Dragoş ^a   Kouremenos, Nikos ^b   Zacharopoulou, Ioanna ^b   Ionac, Adina ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

Anthracyclinemediated cardiomyopathy; Global longitudinal strain; Myocardial deformation; Tridimensional strain imaging

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; BIOLOGICAL MARKER; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; TROPONIN T; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CARDIOTOXICITY; CHEMILUMINESCENCE IMMUNOASSAY; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; PREDICTOR VARIABLE; RELAXATION TIME; THREE DIMENSIONAL ECHOCARDIOGRAPHY; THREE DIMENSIONAL GLOBAL CIRCUMFERENTIAL STRAIN ANALYSIS; THREE DIMENSIONAL GLOBAL LONGITUDINAL STRAIN ANALYSIS; THREE DIMENSIONAL GLOBAL RADIAL STRAIN ANALYSIS; BLOOD; ECHOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; MIDDLE AGED; NEOPLASMS; STATISTICAL MODEL;

ADULT; ANTHRACYCLINES; CARDIOTOXICITY; ECHOCARDIOGRAPHY, THREE-DIMENSIONAL; FEMALE; HEART VENTRICLES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEOPLASMS; PEPTIDE FRAGMENTS; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 84901500938     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE- 4 data. Lancet Oncol. 2007; 8: 784-796.
2. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998; 339: 900-905.
3. Lotrionte M, Palazzoni G, Natali R, et al. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. Int J Cardiol. 2009; 135: 72-77.
4. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011; 57: 2263-2270.
5. Reant P, Barbot L, Touche C, et al. Evaluation of global left ventricular systolic function using three-dimensional echocardiography speckle-tracking strain parameters. J Am Soc Echocardiogr. 2012; 25: 68-79.
6. Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol. 2004; 44: 878-886.
7. Saito K, Okura H, Watanabe N, et al. Comprehensive evaluation of left ventricular strain using speckle tracking echocardiography in normal adults: comparison of three-dimensional and two-dimensional approaches. J Am Soc Echocardiogr. 2009; 22: 1025-1030.
8. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010; 144: 3-15.
9. Martín M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist. 2009; 14: 1-11.
10. Herait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue-are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer. 1992; 28A: 1670-1676.
11. Casazza AM, Bertazzoli C, Pratesi G, Bellini O, Di Marco A. Antileukemic activity and cardiac toxicity of 4-demothoxy (4- DMD) in mice. Proceedings of the American Association for Cancer research. 1970; 20: 16-16.
12. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7: 79-108.
13. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002; 15: 167-184.
14. Hansegård J, Urheim S, Lunde K, Malm S, Rabben SI. Semi-automated quantification of left ventricular volumes and ejection fraction by real-time three-dimensional echocardiography. Cardiovasc Ultrasound. 2009; 7: 18.
15. Cardinale D, Colombo A, Lamantia G, et al. Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55: 213-220.
16. Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol. 2007; 7: 61-66.
17. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009; 53: 2231-2247.
18. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010; 56: 1644-1650.
19. Motoki H, Koyama J, Nakazawa H, et al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012; 13: 95-103.
20. Tsai HR, Gjesdal O, Wethal T, et al. Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. Am J Cardiol. 2011; 107: 472-477.
21. Jurcut R, Wildiers H, Ganame J, et al. Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr. 2008; 21: 1283-1289.
22. Stoodley PW, Richards DA, Hui R, et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr. 2011; 12: 945-952.
23. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011; 107: 1375-1380.
24. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J. 2009; 158: 294-301.
25. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin- induced systolic dysfunction in humans. J Am Coll Cardiol. 1992; 20: 62-69.
26. Ganame J, Claus P, Eyskens B, et al. Acute cardiac functional and morphological changes after Anthracycline infusions in children. Am J Cardiol. 2007; 99: 974-977.
27. Takeda S, Rimington H, Smeeton N, Chambers J. Long axis excursion in aortic stenosis. Heart. 2001; 86: 52-56.
28. Henein MY, Gibson DG. Abnormal subendocardial function in restrictive left ventricular disease. Br Heart J. 1994; 72: 237-242.
29. Newby LK, Rodriguez I, Finkle J, et al. Troponin measurements during drug development-considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. Am Heart J. 2011; 162: 64-73.
30. Dimos AK, Stougiannos PN, Trikas AG. "First, do no harm": chemotherapy or healthy heart? Hellenic J Cardiol. 2012; 53: 127-136.
31. Romano S, Fratini S, Ricevuto E, et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer. 2011; 105: 1663-1668.